
Warrant reveals close calls, victim's attempt to paddle away before deadly Grapevine Lake jet ski crash
On Sunday, 18-year-old Ava Moore was kayaking at Grapevine Lake when she was struck and killed by a jet ski with two women on it, police said. The suspected driver of the jet ski, Daikerlyn Alejandra Gonzalez Gonzalez was taken into custody Tuesday after fleeing the scene with a man.
Attorney General Ken Paxton said that Gonzalez and the man, Maikel Coello, are both undocumented immigrants.
Jet ski operators had close calls before the deadly hit-and-run
Witnesses told Grapevine police that the driver of the jet ski made several passes along the shoreline "with wanton disregard to the safety of others and at a speed and manner that endangered others in the area" before hitting one of two kayaks paddling near the shoreline.
The other kayaker told police that after the jet ski made several passes near the shoreline and near swimmers at a high rate of speed, she and Moore decided to paddle away from the area.
Victim was trying to paddle to safety when she was hit
Ava Moore
Ke'Sha Blanton
As they paddled away, the warrant states, the jet ski driven by Gonzalez hit Moore's kayak from behind.
The other kayaker told police she heard waves approaching and turned her head in time to see the jet ski drive over Moore's kayak.
She also told police she watched Gonzalez turn the jet ski back toward the direction they had just come from and saw Gonzalez and the jet ski passenger, Clerismar Colina-Lugo, "witness that they had recklessly caused injury or death" to Moore. Gonzalez and the passenger then left the area.
Witnesses try to stop suspect in deadly jet ski crash from fleeing
Gonzalez and Colina-Lugo eventually returned to the area on the jet ski, the warrant states, whereupon onlookers and bystanders tried to box in and block the two women from leaving. According to the warrant, witness videos confirm the onlookers' efforts as well as other individuals guarding and helping Gonzalez and Colina-Lugo move towards vehicles in the parking lot.
Daikerlyn Gonzalez, Maikel Coello
Gonzalez is then seen getting into a blue Toyota Corolla with a man later identified as Coello, as the two left the area before crashing into another vehicle and driving away.
Gonzalez faces charges of reckless operation and excessive speed, manslaughter and leaving the scene of an accident.
Coello's charges are currently unknown.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.